Author's Reply to: "Comment on: Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials Including 31,397 Subjects Worldwide"...Konipineni S, Valecha J, Meme CD, et al. Am J Cardiovasc Drugs 26, 507–509 (2026).
This letter addresses the use of trial sequential analysis (TSA) in evaluating colchicine for secondary prevention of cardiovascular disease (CVD), responding to comments by Konipineni et al. The authors acknowledge TSA’s benefits but highlight its limitations, including sensitivity to assumptions a...
| Publicado en: | American Journal of Cardiovascular Drugs Vol. 26; no. 4; pp. 511 - 513 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | letter response Journal Article |
| Publicado: |
Springer Nature
Jul2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |